Emergent BioSolutions (EBS) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Okay. Speaker1 Good afternoon, and welcome to the Jefferies Global Healthcare Conference. My name is Victoria Gendron with the Jefferies Investment Banking Team, and it is with my great pleasure to introduce Richard Lindahl, the CFO of Emergent BioSolutions. Speaker0 Okay. Thank you very much, Victoria, and, thank you all for coming today. We appreciate your interest in our company. I'm going to start, with the standard safe harb ...

Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victor ...

Emergent BioSolutions (EBS) Conference Summary Company Overview - Emergent BioSolutions is a biopharma company with a focus on biodefense and medical countermeasures, established for over 25 years [2][3] - The company produces critical products for the U.S. Government and allied nations, including vaccines and therapeutics for smallpox, anthrax, Ebola, and botulism [3][4][22] Core Products and Market Position - Key products include: - Tymbexa (smallpox vaccine) - Sifendis (anthrax vaccine) - BioThrax (anthrax treatment) - Ibanga (Ebola treatment) - Narcan (opioid overdose reversal) [21][22][30] - Narcan is the largest product, with a market share of approximately 70-75% in the naloxone category [37] Financial Performance and Strategic Plan - Emergent aims for revenue between $750 million to $850 million and adjusted EBITDA of $150 million to $200 million for fiscal 2025 [43] - Adjusted EBITDA improved from negative in 2023 to $183 million in 2024, indicating a successful stabilization phase [14][43] - The company is currently in a turnaround phase, focusing on investments in R&D and business development to drive growth [15][41] Challenges and Opportunities - The company faced significant debt issues, which have been addressed through debt reduction and maturity extensions [9][12] - Emergent is working to enhance the accessibility of Narcan, aiming to include it in first aid kits and increase distribution through partnerships with retailers and e-commerce platforms [30][34][36] Regulatory and Market Environment - Emergent benefits from bipartisan support for biodefense initiatives, which is crucial for securing government contracts [20] - The company manufactures products in the U.S. and Canada, minimizing the impact of tariffs and aligning with reshoring trends in the pharmaceutical industry [48][50] Future Aspirations - The long-term goal is to transform Emergent into a sustainable growth company, with a focus on reducing opioid overdose deaths and expanding international market presence [57][58] - The company aims to leverage its CDMO capabilities to assist other pharmaceutical companies in bringing manufacturing back to the U.S. [51][53] Conclusion - Emergent BioSolutions is positioned to play a critical role in public health through its innovative products and strategic initiatives aimed at addressing pressing health threats, particularly in the context of opioid overdoses and biodefense [36][57]

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York)Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via webcast Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark’s 5th Annual Healthcare House Call Virtual Investor ConferencePres ...

Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 44.90%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.35 per share when it actually produced earnings of $0.05, delivering a surprise of 114.29%.Over the last four ...

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Frank Vargo - VP - Assistant TreasurerJoseph Papa - CEO, President & DirectorRichard Lindahl - EVP, CFO & TreasurerYi Chen - Managing Director, Equity Research Conference Call Participants Jessica Fye - Managing Director & Equity Research Analyst - Biotechnology Operator Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. A ...

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Please be advised that today's conference is being recorded. I wo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 14-1902018 (State or Other Jurisdiction o ...

Q1 2025 Financial Results May 7, 2025 1 Safe Harbor Statement/Trademarks There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine Adsorbed (AVA) Adjuvanted), previously known as AV7909, and ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), ...

| ($ in millions, except per share amounts) | | Q1 2025 | | Q1 2024 | % Change | | --- | --- | --- | --- | --- | --- | | Total Revenues | $ | 222.2 | $ | 300.4 | (26)% | | Net Income | $ | 68.0 | $ | 9.0 | 656 % | | Net Income per Diluted Share | $ | 1.19 | $ | 0.17 | 600 % | | (2) Adjusted Net Income | $ | 40.7 | $ | 31.1 | 31 % | | (2) Adjusted Net Income per Diluted Share | $ | 0.71 | $ | 0.59 | 20 % | | (2) Adjusted EBITDA | $ | 77.6 | $ | 66.9 | 16 % | | (2) Adjusted EBITDA Margin | | 35 % | | 22 % | | ...